Clinical trial
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
NCT00080223 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2003
- Completion date
- April 30, 2015
- Enrollment
- 83 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.